Skip to main content

AFMD

Stock
Health Care
Biotechnology

Performance overview

AFMD Price
Price Chart

Forward-looking statistics

Beta
1.90
Risk
88.55%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Company info

SectorHealth Care
IndustryBiotechnology
Employees113
Market cap$93.5M

Fundamentals

Enterprise value
Revenue
Revenue per employee
Profit margin
Debt to equity

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)
Dividend per share
Revenue per share
Avg trading volume (30 day)
Avg trading volume (10 day)
Put-call ratio

Macro factor sensitivity

Growth+7.5
Credit+2.2
Liquidity-2.8
Inflation+4.9
Commodities+1.7
Interest Rates-2.0

Valuation

Dividend yield0.00%
PEG Ratio
Price to sales
P/E Ratio-0.07
Enterprise Value to Revenue
Price to book

Upcoming events

Next earnings dayJune 12, 2024
Next dividend day
Ex. dividend day

News

AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy

The FDA bestows a Regenerative Medicine Advanced Therapy tag to Affimed's acimtamig in combination with AlloNK for treating Hodgkin lymphoma. Shares fall.

Zacks Investment Research (December 6, 2024)
Affimed Touts Encouraging Patient Responses For Its NK Cell Therapy In Lymphoma Settings

Affimed N.V. (NASDAQ: AFMD) provided a data update from its ongoing study of lead innate cell engager (ICE) AFM13 precomplexed with cord blood-derived natural killer (cbNK) cells.

Benzinga (April 11, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free